Author: Ravi Shankar

• Collaboration extends existing relationship with the Tier 1 pharmaceutical customer into cell therapy programs
• End-to-end supply chain combines 4basebio’s proprietary opDNA® enzymatic DNA starting material with TriLink’s industry-leading GMP mRNA manufacturing capabilities and proprietary CleanCap® co-transcriptional capping technology

CAMBRIDGE, UK – 28 September, 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clinical-grade opDNA® starting material for a multi-national pharmaceutical innovator’s (“the Client”) latest cell therapy program.

Under the agreement, 4basebio will supply synthetic DNA to be used as a critical material for the Client’s upcoming Phase I clinical trial. TriLink BioTechnologies (TriLink), part of Maravai LifeSciences has been selected as the contract development and manufacturing organisation (CDMO) to manufacture the mRNA drug substance, applying its proprietary CleanCap® co-transcriptional capping technology. The agreement reflects 4basebio’s commitment and mission to provide a safer, cost-effective replacement for plasmid DNA in the development of genetic medicines.

Christine Wolosin, Chief Commercial Officer at 4basebio, added: “We’re excited to continue our relationship with this leading pharmaceutical innovator as they advance new molecules into the clinic. This collaboration is a testament to the quality and consistency of our opDNA® platform, and to the strength of the partnerships we’ve built across the CDMO ecosystem. Working alongside TriLink – a world-class mRNA manufacturer – allows us to plug our starting material seamlessly into established manufacturing workflows, giving customers a faster, lower-risk path to the clinic without having to change how they already work with their chosen manufacturing partners.”

Chad Decker, Senior Vice President, Global Sales at TriLink commented: “TriLink is proud to be the CDMO of choice for this important cell therapy program. With our CleanCap® technology paired with 4basebio’s high-purity opDNA® as starting material, we can offer this program with exceptional consistency from DNA template through finished drug substance. This is exactly the kind of end-to-end, quality-forward collaboration that accelerates programs from IND to first patient. We look forward to applying our mRNA manufacturing expertise to help bring this therapy closer to patients.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

4basebio PLC

Dr Amy Walker, CEO

+44 (0)12 2396 7943

Cairn Financial Advisers LLP (Nominated Adviser)

Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880

Cavendish Capital Markets Limited (Joint Broker)

Geoff Nash +44 (0)20 7220 0500

RBC Capital Markets (Joint Broker)

Kathryn Deegan / Sandrine Cailleteau +44 (0)20 7653 4000

ICR Healthcare (Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson +44 (0)203 707 5700

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.

For more information, visit 4basebio.com.

About TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company’s portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap® capping analogs and ModTail® technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.

For more information, visit trilinkbiotech.com

About Maravai LifeSciences

Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

For more information, visit Maravai.com

Forward-looking statements

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

• Collaboration extends existing relationship with the Tier 1 pharmaceutical customer into cell therapy programs
• End-to-end supply chain combines 4basebio’s proprietary opDNA® enzymatic DNA starting material with TriLink’s industry-leading GMP mRNA manufacturing capabilities and proprietary CleanCap® co-transcriptional capping technology

CAMBRIDGE, UK – 28 September, 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clinical-grade opDNA® starting material for a multi-national pharmaceutical innovator’s (“the Client”) latest cell therapy program.

Under the agreement, 4basebio will supply synthetic DNA to be used as a critical material for the Client’s upcoming Phase I clinical trial. TriLink BioTechnologies (TriLink), part of Maravai LifeSciences has been selected as the contract development and manufacturing organisation (CDMO) to manufacture the mRNA drug substance, applying its proprietary CleanCap® co-transcriptional capping technology. The agreement reflects 4basebio’s commitment and mission to provide a safer, cost-effective replacement for plasmid DNA in the development of genetic medicines.

Christine Wolosin, Chief Commercial Officer at 4basebio, added: “We’re excited to continue our relationship with this leading pharmaceutical innovator as they advance new molecules into the clinic. This collaboration is a testament to the quality and consistency of our opDNA® platform, and to the strength of the partnerships we’ve built across the CDMO ecosystem. Working alongside TriLink – a world-class mRNA manufacturer – allows us to plug our starting material seamlessly into established manufacturing workflows, giving customers a faster, lower-risk path to the clinic without having to change how they already work with their chosen manufacturing partners.”

Chad Decker, Senior Vice President, Global Sales at TriLink commented: “TriLink is proud to be the CDMO of choice for this important cell therapy program. With our CleanCap® technology paired with 4basebio’s high-purity opDNA® as starting material, we can offer this program with exceptional consistency from DNA template through finished drug substance. This is exactly the kind of end-to-end, quality-forward collaboration that accelerates programs from IND to first patient. We look forward to applying our mRNA manufacturing expertise to help bring this therapy closer to patients.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

4basebio PLC

Dr Amy Walker, CEO

+44 (0)12 2396 7943

Cairn Financial Advisers LLP (Nominated Adviser)

Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880

Cavendish Capital Markets Limited (Joint Broker)

Geoff Nash +44 (0)20 7220 0500

RBC Capital Markets (Joint Broker)

Kathryn Deegan / Sandrine Cailleteau +44 (0)20 7653 4000

ICR Healthcare (Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson +44 (0)203 707 5700

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.

For more information, visit 4basebio.com.

About TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company’s portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap® capping analogs and ModTail® technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.

For more information, visit trilinkbiotech.com

About Maravai LifeSciences

Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

For more information, visit Maravai.com

Forward-looking statements

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

Accomplished executive to lead strategy and corporate development function driving TransUnion’s next chapter of global growth and innovation

CHICAGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Malte Bernholz will join TransUnion (NYSE: TRU) as Executive Vice President, Chief Strategy and Corporate Development Officer, effective today.

In this newly created role, Bernholz will lead TransUnion’s Enterprise Strategy and Corporate Development function, aligning the organization around a long-term strategy to drive global innovation and scale. He will report to TransUnion President and Chief Executive Officer Chris Cartwright and serve on the executive leadership team.

“TransUnion is expanding how we use data, analytics and technology to drive growth from our broader range of solutions across markets globally, building up our leadership in Credit,” said Cartwright. “I’m confident Malte will strengthen our ability to shape strategy, execute enterprise change, monetize our assets and acquire new capabilities.”

Bernholz will join TransUnion with significant experience leading corporate strategy, M&A and large-scale organizational transformation across global software businesses, private equity investments, and top-tier consulting. Most recently at Adobe, he oversaw enterprise-wide growth strategy across the company’s creativity, productivity and customer experience businesses, and founded and scaled its new product incubator. Prior to Adobe, he served as Vice President of Corporate Strategy Consulting at EMC, as well as Chief Operating Officer at iVize and a consultant at McKinsey & Company. He earned an M.S. from Institut Polytechnique de Grenoble.

“Driving growth in the era of agentic AI requires every organization to develop strategy, plan and execute differently to meet customer needs,” said Bernholz. “I’m excited to join TransUnion at the most innovative point in its history and accelerate how we scale that innovation around the world.”
  
About TransUnion (NYSE: TRU)
TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good^® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business.

Contact	Dave Blumberg
	TransUnion
E-mail	david.blumberg@transunion.com
Telephone	312-972-6646

Accomplished executive to lead strategy and corporate development function driving TransUnion’s next chapter of global growth and innovation

CHICAGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Malte Bernholz will join TransUnion (NYSE: TRU) as Executive Vice President, Chief Strategy and Corporate Development Officer, effective today.

In this newly created role, Bernholz will lead TransUnion’s Enterprise Strategy and Corporate Development function, aligning the organization around a long-term strategy to drive global innovation and scale. He will report to TransUnion President and Chief Executive Officer Chris Cartwright and serve on the executive leadership team.

“TransUnion is expanding how we use data, analytics and technology to drive growth from our broader range of solutions across markets globally, building up our leadership in Credit,” said Cartwright. “I’m confident Malte will strengthen our ability to shape strategy, execute enterprise change, monetize our assets and acquire new capabilities.”

Bernholz will join TransUnion with significant experience leading corporate strategy, M&A and large-scale organizational transformation across global software businesses, private equity investments, and top-tier consulting. Most recently at Adobe, he oversaw enterprise-wide growth strategy across the company’s creativity, productivity and customer experience businesses, and founded and scaled its new product incubator. Prior to Adobe, he served as Vice President of Corporate Strategy Consulting at EMC, as well as Chief Operating Officer at iVize and a consultant at McKinsey & Company. He earned an M.S. from Institut Polytechnique de Grenoble.

“Driving growth in the era of agentic AI requires every organization to develop strategy, plan and execute differently to meet customer needs,” said Bernholz. “I’m excited to join TransUnion at the most innovative point in its history and accelerate how we scale that innovation around the world.”
  
About TransUnion (NYSE: TRU)
TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good^® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business.

Contact	Dave Blumberg
	TransUnion
E-mail	david.blumberg@transunion.com
Telephone	312-972-6646

• Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
• Eton has integrated full Eton Cares^® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs
• Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO^® (miltefosine) capsules.

“We are excited to be relaunching IMPAVIDO and making Eton Cares available to all patients. By bringing IMPAVIDO into Eton’s rare disease commercial infrastructure, we can pair this important therapy with high-touch services designed to help support healthcare providers and expand access for patients. We believe this comprehensive approach will help ensure that patients who need IMPAVIDO can access and initiate treatment without unnecessary delays. We are also working to expand hospital on-site availability across the United States through our consignment inventory stocking program,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Clinicians seeking to prescribe IMPAVIDO can e-prescribe by selecting Anovo #5 (Memphis) or fax a patient referral form to 855-813-2039. Patients with questions regarding their prescription or healthcare providers can call Anovo at the dedicated IMPAVIDO line 877-469-4078.

Hospital pharmacies seeking IMPAVIDO for inpatient use may contact Anovo Specialty Pharmacy to establish access through the hospital network.

For urgent or time-sensitive patient needs, Anovo will coordinate an emergency access pathway with treating clinicians, CDC representatives, and hospital pharmacies. The pathway is designed to evaluate the fastest available source of product and delivery option based on the patient’s need-by time and the treating institution’s location.

Additional product details can be found on the product website, www.impavidous.com.

Important Safety Information for IMPAVIDO

INDICATION

IMPAVIDO® (miltefosine) is an antileishmanial drug indicated in adults and adolescents ≥12 years of age weighing ≥30 kg (66 lbs) for treatment of:

• Visceral leishmaniasis due to Leishmania donovani.
• Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis.
• Mucosal leishmaniasis due to Leishmania braziliensis.

Limitations of Use: Leishmania species evaluated in clinical trials were based on epidemiologic data. There may be geographic variation in the response of the same Leishmania species to IMPAVIDO. The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.

IMPORTANT SAFETY INFORMATION

Contraindications

IMPAVIDO is contraindicated in pregnancy because it may cause fetal harm; in patients with Sjögren-Larsson syndrome; and in patients with hypersensitivity to miltefosine or any component of the formulation.

Warnings and Precautions

Embryo-Fetal Toxicity: IMPAVIDO may cause fetal harm when administered during pregnancy. Obtain a pregnancy test before initiating therapy in females of reproductive potential. Advise females of reproductive potential to use effective contraception during treatment and for 5 months after completion of therapy. If vomiting or diarrhea occurs during treatment, oral contraceptive effectiveness may be reduced; advise use of an additional non-hormonal contraceptive method.

Reproductive Effects: Miltefosine caused impaired fertility in animal studies. The potential effects on human fertility have not been adequately evaluated.

Renal Effects: Monitor serum creatinine during treatment and for 4 weeks after completion of therapy.

Hepatic Effects: Monitor liver transaminases and bilirubin during treatment.

Gastrointestinal Effects: Vomiting and diarrhea are common and may result in dehydration. Encourage adequate fluid intake during treatment.

Thrombocytopenia: Monitor platelet counts during therapy in patients treated for visceral leishmaniasis.

Stevens-Johnson Syndrome: Stevens-Johnson syndrome has been reported. Discontinue IMPAVIDO if an exfoliative or bullous rash develops.

Adverse Reactions

The most common adverse reactions (≥2%) are nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, and elevated serum creatinine.

To report a suspected adverse event related to IMPAVIDO, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/MedWatch or call 1-800-FDA-1088.

Please see Full Prescribing Information, including Boxed Warning regarding Embryo-Fetal Toxicity.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI^® (hydrocortisone), INCRELEX^® (mecasermin), ALKINDI SPRINKLE^® (hydrocortisone), DESMODA^™ (desmopressin acetate), GALZIN^® (zinc acetate), HEMANGEOL^® (propranolol hydrochloride), PKU GOLIKE^®, IMPAVIDO^® (miltefosine), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: AMGLIDIA^® (glyburide), ASN-001, ET-700, ET-800, and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

• Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
• Eton has integrated full Eton Cares^® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs
• Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO^® (miltefosine) capsules.

“We are excited to be relaunching IMPAVIDO and making Eton Cares available to all patients. By bringing IMPAVIDO into Eton’s rare disease commercial infrastructure, we can pair this important therapy with high-touch services designed to help support healthcare providers and expand access for patients. We believe this comprehensive approach will help ensure that patients who need IMPAVIDO can access and initiate treatment without unnecessary delays. We are also working to expand hospital on-site availability across the United States through our consignment inventory stocking program,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Clinicians seeking to prescribe IMPAVIDO can e-prescribe by selecting Anovo #5 (Memphis) or fax a patient referral form to 855-813-2039. Patients with questions regarding their prescription or healthcare providers can call Anovo at the dedicated IMPAVIDO line 877-469-4078.

Hospital pharmacies seeking IMPAVIDO for inpatient use may contact Anovo Specialty Pharmacy to establish access through the hospital network.

For urgent or time-sensitive patient needs, Anovo will coordinate an emergency access pathway with treating clinicians, CDC representatives, and hospital pharmacies. The pathway is designed to evaluate the fastest available source of product and delivery option based on the patient’s need-by time and the treating institution’s location.

Additional product details can be found on the product website, www.impavidous.com.

Important Safety Information for IMPAVIDO

INDICATION

IMPAVIDO® (miltefosine) is an antileishmanial drug indicated in adults and adolescents ≥12 years of age weighing ≥30 kg (66 lbs) for treatment of:

• Visceral leishmaniasis due to Leishmania donovani.
• Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis.
• Mucosal leishmaniasis due to Leishmania braziliensis.

Limitations of Use: Leishmania species evaluated in clinical trials were based on epidemiologic data. There may be geographic variation in the response of the same Leishmania species to IMPAVIDO. The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.

IMPORTANT SAFETY INFORMATION

Contraindications

IMPAVIDO is contraindicated in pregnancy because it may cause fetal harm; in patients with Sjögren-Larsson syndrome; and in patients with hypersensitivity to miltefosine or any component of the formulation.

Warnings and Precautions

Embryo-Fetal Toxicity: IMPAVIDO may cause fetal harm when administered during pregnancy. Obtain a pregnancy test before initiating therapy in females of reproductive potential. Advise females of reproductive potential to use effective contraception during treatment and for 5 months after completion of therapy. If vomiting or diarrhea occurs during treatment, oral contraceptive effectiveness may be reduced; advise use of an additional non-hormonal contraceptive method.

Reproductive Effects: Miltefosine caused impaired fertility in animal studies. The potential effects on human fertility have not been adequately evaluated.

Renal Effects: Monitor serum creatinine during treatment and for 4 weeks after completion of therapy.

Hepatic Effects: Monitor liver transaminases and bilirubin during treatment.

Gastrointestinal Effects: Vomiting and diarrhea are common and may result in dehydration. Encourage adequate fluid intake during treatment.

Thrombocytopenia: Monitor platelet counts during therapy in patients treated for visceral leishmaniasis.

Stevens-Johnson Syndrome: Stevens-Johnson syndrome has been reported. Discontinue IMPAVIDO if an exfoliative or bullous rash develops.

Adverse Reactions

The most common adverse reactions (≥2%) are nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, and elevated serum creatinine.

To report a suspected adverse event related to IMPAVIDO, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/MedWatch or call 1-800-FDA-1088.

Please see Full Prescribing Information, including Boxed Warning regarding Embryo-Fetal Toxicity.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI^® (hydrocortisone), INCRELEX^® (mecasermin), ALKINDI SPRINKLE^® (hydrocortisone), DESMODA^™ (desmopressin acetate), GALZIN^® (zinc acetate), HEMANGEOL^® (propranolol hydrochloride), PKU GOLIKE^®, IMPAVIDO^® (miltefosine), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: AMGLIDIA^® (glyburide), ASN-001, ET-700, ET-800, and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — FTAI Energy Partners LLC (“Jefferson” or the “Company”), a subsidiary of FTAI Infrastructure Inc. (NASDAQ: FIP), today announced that its subsidiary has entered into a definitive agreement to acquire the Port Arthur Terminal in Port Arthur, Texas, and a 50% interest in the Diluent Recovery Unit (“DRU”) located in Hardisty, Alberta, from a subsidiary of USD Group LLC (“USDG”). The total acquisition consideration is approximately $255 million in cash and will be financed by assuming existing indebtedness of the acquired business and with an acquisition debt facility secured by Jefferson and its subsidiaries. The Company expects the acquired assets to generate approximately $50 million of annual EBITDA over the next twelve months. Closing of the transaction is subject to the receipt of required regulatory approvals which are expected during the fourth quarter of 2026.

“The acquisition of USD’s assets is an ideal fit and highly accretive for our Jefferson segment, more than doubling Jefferson’s existing Adjusted EBITDA with contracted cash flow under a long-term agreement with minimum volume commitments from an investment grade counterparty. The transaction significantly de-leverages Jefferson’s balance sheet and, we believe, creates substantial incremental value at Jefferson” said Ken Nicholson, Chief Executive Officer of FTAI Infrastructure.

The acquired assets represent an integrated origin-to-destination logistics platform for the shipment of crude oil into the Beaumont refinery hub under a long-term, take-or-pay contract with a major energy exploration and production company. The Port Arthur Terminal is designed to handle approximately 50,000 barrels per day of crude oil arriving by rail which is further shipped to customers via an owned 12-mile, 24-inch diameter pipeline system connecting to P66’s Beaumont terminal for distribution to local refiners in Beaumont, Lake Charles and other key Gulf Coast markets.

Hank Alexander, CEO of Jefferson said, “Combining the USDG assets with our existing Jefferson terminals is a game-changer for our platform, adding a new long-term customer to our revenue base and providing multiple growth opportunities ahead. We look forward to working with USDG’s team of high quality professionals to continue to grow the acquired assets as well as our existing Jefferson business.”

Jefferson has obtained a commitment for acquisition financing which will enable it to fund the acquisition. In addition, the Company expects to evaluate combining the acquired assets with its existing subsidiary, Jefferson Bond Borrower LLC, which presently owns Jefferson’s main terminal business and a portion of the Jefferson South terminal, and funding the acquisition with the issuance of Additional Parity Bonds under the indenture for Jefferson Bond Borrower LLC.

Jefferies and Houlihan Lokey served as financial advisors to the Company and USDG, respectively. Barclays served as capital finance advisor to Jefferson in connection with arranging funding for the transaction. Vinson & Elkins LLP, Bennett Jones LLP and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisors to the Company, and Gibson, Dunn & Crutcher LLP acted as legal advisors to USDG.

About Jefferson Energy Companies

Jefferson is a midstream energy infrastructure company headquartered in Houston, Texas, with terminal operations at the Port of Beaumont, one of North America’s largest refining and petrochemical centers. Jefferson Energy’s multimodal terminal facilities provide transloading, storage, handling, blending, and related services for products including crude oil, refined products, and ammonia, with direct access to rail, highway, and marine transportation.

About FTAI Infrastructure Inc.

FTAI Infrastructure Inc. primarily invests in critical infrastructure with high barriers to entry across the rail, ports and terminals, and power and gas sectors that, on a combined basis, generate strong and stable cash flows with the potential for earnings growth and asset appreciation. FTAI Infrastructure is externally managed by an affiliate of Fortress Investment Group LLC, a leading, diversified global investment firm.

Non-GAAP Metrics

EBITDA is defined as net income (loss) attributable to stockholders, adjusted to exclude the impact of provision for (benefit from) income taxes, depreciation and amortization expense and interest expense. Jefferson is not providing forward looking guidance for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort. These items include, but are not limited to, interest expense, contractor costs and customer revenues. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected closing of the transaction, anticipated financing arrangements, projected EBITDA, future operating performance, expected strategic benefits, customer demand, market conditions and anticipated growth opportunities. These statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, the satisfaction of closing conditions, regulatory approvals, financing availability, market conditions, commodity price volatility, customer demand and other risks described in the filings of FTAI Infrastructure Inc. with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

For further information please contact:

Alan Andreini
Investor Relations
FTAI Infrastructure Inc.
(646) 734-9414

NEWPORT BEACH, CA, Sept. 28, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (NYSE American: BESS) (“Bimergen”), a U.S. energy infrastructure developer, owner and operator, announces that its Board of Directors has authorized an open-market warrant repurchase program to buyback any or all its publicly traded warrants (Ticker: BESSWS).

The program aims to opportunistically deploy capital to reduce future equity dilution while capitalizing on the then current market pricing. Under the authorization, the Company may purchase warrants from time to time on the open market, through block trades, or via privately negotiated transactions in each case in compliance with applicable federal securities laws, including Sections 9(a)(2) and 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder, SEC rules and regulations, and NYSE American requirements. The timing and actual volume of repurchases will depend on prevailing market conditions, liquidity, and trading volumes and applicable regulatory requirements as determined by management. The program does not obligate the Company to acquire any specific amount of warrants and may be suspended or discontinued at any time.

“We have not yet established brokerage accounts to execute the authorized warrant buyback,” said Bob Brilon, Co-CEO of Bimergen Energy. “By the Board authorizing this open-market buyback program, we as management, can be ready to efficiently use our cash positions to reduce potential dilution, optimize our equity architecture, and build long-term value for our common stockholders as appropriate.”

“Closing transactions for high-quality battery energy storage projects is our focused strategy,” said Cole W. Johnson, Co-CEO of Bimergen Energy. “The flexibility of the buyback program and reduction of equity overhang is viewed as a positive by current and potential strategic partners.”

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS) is a U.S.-based renewable energy developer, asset owner and operator focused on utility-scale battery energy storage system (BESS) projects. The operating revenue generation comes from buying energy at lower off-peak prices and selling them back to the same grid at higher peak prices. Bimergen develops and operates infrastructure designed to enhance grid stability and support the integration of renewable generation across key U.S. markets, maintaining a diversified pipeline and partnering with institutional capital providers to advance projects through construction and long-term operation. Learn more at www.Bimergen.com.

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Bimergen Energy Corporation’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Bimergen Energy Corporation undertakes no duty to update such information except as required under applicable law.

Contact:
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
BESS@redchip.com

Company Announcement

Copenhagen, 28 September 2026
No. 60/2026

Transactions in connection with share buyback programme
ISS A/S, a leading workplace experience and facility management company, announced on 19 February 2026 a new share buyback programme, see company announcement no. 10/2026. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Regulation.

Through the programme, ISS wishes to redistribute excess cash to shareholders. The purpose of the share buy-back programme is to (i) reduce the share capital and (ii) meet obligations arising from ISS’ share-based incentive programmes.

Under the programme, ISS will repurchase shares for a maximum consideration of DKK 3.1 billion, including approx. DKK 1.25 billion related to the completed first tranche, over a 12-month period from 19 February 2026 to 22 February 2027 at the latest, both days inclusive. The second tranche of up to DKK 1.85 billion commenced on 11 August 2026 and will complete no later than 22 February 2027.

The following transactions have been made under the programme:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated, last announcement	6,253,702	261.02	1,632,341,574
21 September 2026	40,000	292.41	11,696,400
22 September 2026	35,000	298.67	10,453,450
23 September 2026	35,000	303.43	10,620,050
24 September 2026	66,000	298.74	19,716,840
25 September 2026	66,000	293.88	19,396,080
Accumulated under the programme	6,495,702	262.36	1,704,224,394

Following the transactions stated above, ISS A/S owns a total of 6,244,077 treasury shares corresponding to 3.90% of the total share capital.

In accordance with the Market Abuse Regulation, the details of each transaction made under the share buyback programme are enclosed.

For investor enquiries
Michael Vitfell-Rasmussen, Head of Group Investor Relations, +45 53 53 87 25
Anne Sophie Riis, Senior Investor Relations Manager, +45 30 52 94 68

For media enquiries
Charlotte Holm, Head of External Communication, +45 41 76 19 89

ISS is a leading, global provider of workplace and facility service solutions. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. ISS has more than 325,000 employees around the globe, who we call “placemakers”. In 2025, Group revenue was DKK 84.7 billion. For more information on the ISS Group, visit www.issworld.com

Attachments

• ISS announcement – SBB week 39
• Appendix_Company_Announcement_NO_39-2026

InstallatørGruppen’s Interim trading statement for the period ending 30 September will be published around 08:00 CEST on 28 October 2026.

The report will be presented on the same day at 10:00 CEST by Group CEO Niels Eldrup Meidahl and Group CFO Mathias Ringsted Grüner. The presentation will be held in English and can be followed on the web or by phone. The presentation will be followed by a Q&A session.

Link to webcast

Telephone conference: To participate and ask questions in the conference call, please register via this link.

The report and presentation will be available here

For further information, please contact: Maximillian Hjorth Beste, Head of M&A and Investor Relations Telephone: +45 2899 2846 E-mail: mhb@i-g.dk